Royalty Pharma plc (RPRX) stock analysis
RPRX · Royalty Pharma plc
Latest recorded price: USD 68.53
Model-estimated fair value: USD 26.54. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Biotechnology
At $68.53, RPRX trades 158.2% above the model's base-case value of $26.54. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $18.31 in the conservative case and $35.71 in the optimistic case, with a valuation confidence score of 55/100. About 77% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 2.1%, ROIC 6.9%. The model does not flag any risk signals for this company.
Similar companies in Healthcare
- Revolution Medicines, Inc. (RVMD)
- Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
- Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)
- SELLAS Life Sciences Group, Inc. - Common Stock (SLS)
- Summit Therapeutics Inc. (SMMT)
- Syndax Pharmaceuticals, Inc. (SNDX)
- Sarepta Therapeutics, Inc. (SRPT)
- Scholar Rock Holding Corporation (SRRK)